Eli Lilly’s GIP/GLP-1 dual receptor agonist Mounjaro (tirzepatide) has demonstrated cardiovascular protection in a late-stage ...

The most widely used measure of health-related self-efficacy is the Patient Activation Measure (PAM). It is a ...

The new initiative, FDA PreCheck, was developed in response to President Donald Trump’s executive order to accelerate the ...

It is hoped the new formulation will offer patients greater freedom and flexibility compared to the liquid version ...

AstraZeneca (AZ) has announced that Imfinzi (durvalumab) in combination with Imjudo (tremelimumab) has been recommended by ...

MSD – known as Merck & Co in the US and Canada – has announced that its anti-PD-1 therapy Keytruda (pembrolizumab) has been ...

The Medscape Global team is bringing their leading cardiology education and proven impact to the European Society of ...

Rezpegaldesleukin, which has already been granted FDA fast track designation for moderate-to-severe atopic dermatitis, is ...

The European Medicines Agency’s human medicines committee has recommended that BeOne Medicines’ Tevimbra (tislelizumab) be ...

Patient engagement is one of the most reliable ways to drive long-term health outcomes and a critical benchmark for ...

This Phase III global clinical trial for patients with either stage IIIB or IV unresectable melanoma involved 118 research ...

Novo Nordisk has announced the appointment of Maziar Mike Doustdar as its new president and chief executive officer (CEO).